| HOME >> MEDICINE >> TECHNOLOGY |
•PharmaVitae Explorer database
EXECUTIVE SUMMARY•Reliance Life Sciences biosimilars overview
•Reliance Life Sciences biosimilars infrastructure
STRATEGIC INSIGHT•Reliance Life Sciences made the strategic acquisition of GeneMedix to penetrate the European markets
•Reliance is focusing on the oncology therapy area and developing a portfolio of MAb biosimilars - Oncology focus
•Reliance Life Sciences biosimilars SWOT analysis - Strengths
- Weaknesses
- Opportunities
- Threats
KEY PRODUCTS•Reliance Life Sciences biosimilars portfolio
•ReliPoietin (epoetin alfa) - Overview
- Erythropoietin market size
- Key competitors
•ReliGrast (filgrastim)Reliance Life Sciences launched biosimilar granulocyte colony-stimulating factor (GCSF) ReliGrast in 2008. It is currently marketed in India and other semi-regulated markets. - Filgrastim and pegfilgrastim market size
- Key competitors
•ReliFeron (interferon alfa-2b) - Overview
- Interferon alfa market size
- Key competitors
•FostiRel (follitropin beta) - Market overview
- Key competitors
•ReliBeta (interferon beta-1a) - Overview
- Interferon beta market size
- Key competitors
- Reliance Life Sciences' other marketed products and biosimilar development
CORPORATE STRUCTURE•Background
•Key corporate developments
•Company structure - Biopharmaceuticals
- Novel therapeutics
- Pharmaceuticals
- Clinical research services
- Regenerative medicine
- Molecular medicine
- Plant biotechnology
- Industrial biotechnology
•Deals and a
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |